UPB insider buying and SEC filings, explained
Upstream Bio, Inc. · CIK 2022626
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$105K
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 16, 2026 | Sale | Aaron Deykin (Chief Medical Officer) sold 895 shares at $5.49 ($5K). Holdings down 3% to 32,302 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 17, 2026 |
| Sep 16, 2026 | Sale | Everett Rand Sutherland (CEO and Director) sold 2,095 shares at $5.49 ($12K). Holdings down 3% to 68,717 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 17, 2026 |
| Sep 16, 2026 | Sale | Adam Houghton (Chief Business Officer) sold 700 shares at $5.49 ($4K). Holdings down 3% to 22,901 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 17, 2026 |
| Sep 16, 2026 | Sale | Michael Gray (CFO) sold 853 shares at $5.49 ($5K). Holdings down 3% to 27,942 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 17, 2026 |
| Sep 16, 2026 | Sale | Allison Ambrose (General Counsel) sold 485 shares at $5.49 ($3K). Holdings down 3% to 15,563 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 17, 2026 |
| Jun 16, 2026 | Sale | Michael Gray (CFO) sold 853 shares at $6.10 ($5K). Holdings down 3% to 28,795 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 17, 2026 |
| Jun 16, 2026 | Sale | Everett Rand Sutherland (CEO and Director) sold 2,095 shares at $6.10 ($13K). Holdings down 3% to 70,812 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 17, 2026 |
| Jun 16, 2026 | Sale | Adam Houghton (Chief Business Officer) sold 700 shares at $6.10 ($4K). Holdings down 3% to 23,601 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 17, 2026 |
| Jun 16, 2026 | Sale | Aaron Deykin (Chief Medical Officer) sold 895 shares at $6.10 ($5K). Holdings down 3% to 33,197 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 17, 2026 |
| Jun 16, 2026 | Sale | Allison Ambrose (General Counsel) sold 477 shares at $6.10 ($3K). Holdings down 3% to 16,048 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 17, 2026 |
| Mar 16, 2026 | Sale | Michael Gray (CFO) sold 852 shares at $9.29 ($8K). Holdings down 3% to 29,648 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 17, 2026 |
| Mar 16, 2026 | Sale | Aaron Deykin (Chief Medical Officer) sold 894 shares at $9.29 ($8K). Holdings down 3% to 32,687 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 17, 2026 |
| Mar 16, 2026 | Sale | Everett Rand Sutherland (CEO and Director) sold 2,093 shares at $9.29 ($19K). Holdings down 3% to 72,907 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 17, 2026 |
| Mar 16, 2026 | Sale | Allison Ambrose (General Counsel) sold 475 shares at $9.29 ($4K). Holdings down 3% to 16,525 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 17, 2026 |
| Mar 16, 2026 | Sale | Adam Houghton (Chief Business Officer) sold 699 shares at $9.29 ($6K). Holdings down 3% to 24,301 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 17, 2026 |
11 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow UPB in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.